Pipeline-in-a-Molecule
TP-317 offers expansion opportunities in multiple immune disorders and
solid tumors across stages of disease.
As an oral small molecule agonist of ChemR23, TP-317 offers a superior product profile compared to injectable monoclonal antibodies targeting the same receptor.
Adjunctive use of TP-317 has prospects to raise the efficacy ceiling encountered by existing therapeutic approaches, with no additional safety burden.
TP-317 product profile and single-agent efficacy supports potential use as chronic therapy for maintenance of remission.
The option of parenteral, inhalable, sublingual or topical formulation is available to enhance therapeutic targeting and support label expansion.